Glioblastoma is the most common type of malignant brain tumor in adults. It is usually very aggressive, with less than 10% of patients expected to survive five years following diagnosis. Traditional treatment strategies are rarely curative, emphasizing the urgent need to discover more effective therapies for this type of cancer.
Read this publication review to learn how researchers have evaluated the efficiency of mRNA-based multifunctional CAR T-cells against glioblastoma in vitro and in vivo. The authors confirm rationale for future clinical studies using this type of therapy to treat malignant brain tumors.